{
    "nctId": "NCT05772390",
    "briefTitle": "Partial Breast Re-irradiation in Women in Women with Locally Recurrent Breast Cancer Previously Treated with Conservative Surgery and Whole Breast Irradiation",
    "officialTitle": "Partial Breast Re-irradiation in Women with Locally Recurrent Breast Cancer Previously Treated with Conservative Surgery and Whole Breast Irradiation: a Prospective Phase II Clinical Study",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Recurrent",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 68,
    "primaryOutcomeMeasure": "Treatment related toxicity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Isolated ipsilateral unifocal breast lesions;\n2. Histologically confirmed invasive breast carcinoma or carcinoma in situ;\n3. Limited size (\\&lt; 2 cm) without evidence of skin involvement;\n4. Negative histologic margins of resection;\n5. Negative axillary lymph nodes;\n6. No synchronous distant metastases;\n7. Bilateral breast mammogram or MRI within 120 days prior to study entry;\n8. For invasive in-breast recurrence, no more than 120 days since whole-body (positron emission tomography) PET-CT scan OR CT scan of the chest, abdomen, and pelvis, and bone scan (if clinically relevant);\n9. \u2265 24 months interval between initial breast conserving therapy (surgery and whole breast radiotherapy) and recurrence;\n10. Female, aged \\&gt;18 years;\n11. Life expectancy of greater than 12 months;\n12. ECOG performance status \\&lt;2;\n13. Female participants of child bearing potential must be willing to ensure that they or their partner use effective contraception during the study and for 4 months thereafter;\n14. Participant is willing and able to give informed consent for participation in the study;\n\nExclusion Criteria:\n\n1. Regional recurrences (axillary, supraclavicular);\n2. Positive histologic margins at resection;\n3. Metastatic disease;\n4. Previous breast RT performed with IORT, brachytherapy or previous partial breast treatment;\n5. Known pathogenic mutation of BRCA1, BRCA2 or TP53 gene;\n6. Patients who had chemotherapy within 2 weeks prior to study RT;\n7. Participation in another clinical trial with any investigational agents within 30 days prior to study screening;\n8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements;\n9. Significant comorbidity precluding RT for breast cancer (cardiovascular or pulmonary disease, sclerodermia, systemic lupus erythematosus);\n10. Other known malignant neoplastic diseases in the patient's medical history with a disease-free interval of less than 5 years (except for previously treated basal cell carcinoma of the skin and in situ carcinoma of the uterine cervix, endometrium or colon);\n11. Inaccessibility for follow-up;",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}